University Medical Center of the Johannes Gutenber Univeristy
Welcome,         Profile    Billing    Logout  
 25 Trials 
12 Trials

   Remove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Galle, Peter R
RENOTACE, NCT04777851: Regorafenib-pembrolizumab Vs. TACE/TARE in Intermediate Stage HCC Beyond Up-to-7

Recruiting
3
496
Europe, Japan, US, RoW
Regorafenib in combination with pembrolizumab, Stivarga® (regorafenib), Keytruda® (pembrolizumab), Loco-regional therapy, Convention transarterial chemoembolization (cTACE), Drug-eluting bead transarterial chemoembolization (DEB-TACE), Transarterial Chemoembolization (TACE), Transarterial radioembolization (TARE)
Translational Research in Oncology, Bayer
Carcinoma, Hepatocellular
10/25
04/27
NCT05733598: Study of RP2 in Combination With Second-line Therapy in Patients With Locally Advanced Unresectable or Metastatic HCC

Recruiting
2
30
US
RP2, Bevacizumab, Avastin, Atezolizumab, Tecentriq
Replimune Inc., Roche Pharma AG
Hepatocellular Carcinoma
12/27
07/28
JADE, NCT04510740: Liver Cancer Registry Platform

Recruiting
N/A
1000
Europe
Physician's choice according to patient's needs.
iOMEDICO AG
Hepatocellular Carcinoma (HCC), Cholangiocarcinoma
12/26
12/26
Neumann, Helmut
COLOWISE, NCT05611151: Real-time Computer-Aided Detection of Colonic Adenomas With NEC WISE VISION® Endoscopy

Completed
N/A
830
Europe, US
Computer Aided Detection (CADe)
NEC Corporation, Meditrial Europe Ltd., Meditrial USA Inc.
Colorectal Cancer, Adenoma Colon, Polyp of Colon
09/24
09/24
Gori, Tommaso
NCT05437900: INSIGHTFUL-FFR Clinical Trial

Recruiting
4
2500
Europe, RoW
Pressure Microcatheter guided strategy - PIOS MC, Pressure Wire guided strategy - PIOS - PW, Pressure Microcatheter guided strategy - Standard of care, Pressure Wire guided strategy - Standard of care
CoreAalst BV, Insight Lifetech Co., Ltd.
Coronary Artery Disease, Acute Coronary Syndrome
06/26
06/30
COSIMA, NCT04606459: COronary SInus Reducer for the Treatment of Refractory Microvascular Angina

Recruiting
N/A
144
Europe
Coronary sinus reducer, Optimal medical therapy
Johannes Gutenberg University Mainz, Neovasc Inc.
Coronary Microvascular Disease, Refractory Angina
10/25
10/29
Schattenberg, Jörn M
NATiV3, NCT04849728: A Phase 3 Study Evaluating Efficacy and Safety of Lanifibranor Followed by an Active Treatment Extension in Adult Patients With (NASH) and Fibrosis Stages F2 and F3 ( )

Recruiting
3
1000
Europe, Canada, US, RoW
IVA337, Lanifibranor, Placebo
Inventiva Pharma
NASH - Nonalcoholic Steatohepatitis
09/25
09/26
Grambihler, Annette
LIMT-2, NCT05070364 / 2021-003665-35: Phase 3 Study to Evaluate the Efficacy and Safety of Peginterferon Lambda for 48 Weeks in Patients With Chronic HDV

Active, not recruiting
3
150
Europe, US, RoW
Peginterferon Lambda-1a, Lambda, Peginterferon Lambda, Pegylated Interferon Lambda
Eiger BioPharmaceuticals, Eiger BioPharmaceuticals, Inc.
Hepatitis Delta Virus
06/24
01/25
Schattenberg, Joern
ARGON-2, NCT04378010 / 2019-003876-38: A Randomized, Double-blind Study to Assess the Safety and Efficacy of EDP-305 in Subjects With Liver-biopsy Proven NASH

Terminated
2b
98
Europe, Canada, US, RoW
EDP-305 1.5 mg, EDP-305, EDP-305 2 mg, Placebo
Enanta Pharmaceuticals, Inc, Enanta Pharmaceuticals, Inc.
Non-Alcoholic Steatohepatitis
10/21
11/21
NormaliZED, NCT05305599 / 2021-002253-29: Different Doses of ZED1227 vs. Placebo in NAFLD

Completed
2
186
Europe
ZED1227, Placebo
Dr. Falk Pharma GmbH, Dr. Falk Pharma GmbH
NAFLD, Liver Fibrosis
06/23
07/23
NCT05479721: LITMUS Imaging Study

Active, not recruiting
N/A
450
Europe, US
University of Oxford, Newcastle University, University of Nottingham, University of Cambridge, University of Seville, Pinnacle Clinical Research, PLLC, ICAN Nutrition Education and Research, Assistance Publique - Hôpitaux de Paris, University of Angers, University of Palermo, University of Turin, Italy, University Medical Center Mainz, University of Helsinki, University of Bern, Linkoeping University, Perspectum, Antaros Medical, Resoundant Inc, Pfizer, Novartis, Takeda, Boehringer Ingelheim, Intercept Pharmaceuticals, Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)
NAFLD, NASH, NASH - Nonalcoholic Steatohepatitis, Fibrosis, Liver, Steatosis of Liver
10/24
10/24
NASH-Biomarker, NCT05312853: Evaluating the Diagnostic and Predictive Value of Non-invasive Tests (NITs) on the Progression of Chronic Liver Disease.

Not yet recruiting
N/A
250
Europe
Johannes Gutenberg University Mainz, Boehringer Ingelheim, Nordic Bioscience A/S
Chronic Liver Disease
04/34
12/34

Download Options